×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
GlobeNewswire
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber...
4 days ago
Lixte CEO Takes On a New Course
Los Angeles Business Journal
Pasadena-based pharmaceutical company Lixte Biotechnology Holdings Inc.'s new chief executive is also charting a new course for the company...
3 months ago
Why Lixte Biotechnology Stock Is Soaring - Lixte Biotechnology (NASDAQ:LIXT)
Benzinga
Lixte Biotechnology Holdings, Inc. LIXT+6.09%. + Free Alerts. shares are trading higher Wednesday after the company announced the...
1 month ago
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER ...
Yahoo Finance
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE...
1 month ago
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
GlobeNewswire
09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage...
7 months ago
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and ...
Yahoo Finance
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb.
2 months ago
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
GlobeNewswire
The Company's novel approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for...
5 months ago
Why Is Lixte Biotech (LIXT) Stock Down 29% Today?
InvestorPlace
Why Is Lixte Biotech (LIXT) Stock Down 29% Today? · Lixte Biotech (LIXT) stock is falling after a rally yesterday. · That came alongside news of...
15 months ago
Beating by overheating: new strategy to combat cancer
EurekAlert!
One could compare cancer cells subjected to the paradoxial approach in this study to the engine of a racing car: if you crank up the RPM and...
1 month ago